Shire plc (SHPG)
-NasdaqGS 119.85 
2.59(2.12%) 4:00PM EDT|After Hours
:
119.94 0.09 (0.08%) 5:23PM EDT
| Prev Close: | 122.44 |
|---|
| Open: | 119.77 |
|---|
| Bid: | 0.01 x 1000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 126.00 |
|---|
| Beta: | 0.65 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 119.07 - 120.08 |
|---|
| 52wk Range: | 81.76 - 124.96 |
|---|
| Volume: | 255,944 |
|---|
| Avg Vol (3m): | 346,366 |
|---|
| Market Cap: | 21.96B |
|---|
| P/E (ttm): | 37.87 |
|---|
| EPS (ttm): | 3.17 |
|---|
| Div & Yield: | 0.18 (0.10%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SHIRE PLC Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Wed 7:14AM EDT)
- A Risky Biotech Stock to Watch?at Motley Fool(Tue, Oct 1)
- SHIRE PLC Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Tue, Oct 1)
- Shire upgraded to Overweight from Neutral at JPMorgantheflyonthewall.com(Mon, Sep 30)
- A Closer Look At Johnson & Johnson's Pharmaceuticals Businessat Motley Fool(Fri, Sep 27)
- First Week of SHPG November 16th Options Tradingat Forbes(Fri, Sep 27)
- SHIRE PLC Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 27)
- SHIRE PLC Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Wed, Sep 25)
- New Management Pushes Medgenics To Forefront Of Gene Therapyat Seeking Alpha(Mon, Sep 23)
- Acceleron Pharma - Successful Cancer Research IPOat Seeking Alpha(Sun, Sep 22)
- SHIRE PLC Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 20)
- Acceleron Pharma IPO Pops; Fate Therapeutics On Deckat Investor's Business Daily(Thu, Sep 19)
- Sangamo Prices SharesZacks(Thu, Sep 19)
- How Far Can $69 Million Take Protalix?at Motley Fool(Wed, Sep 18)
- Analyst Sees Big Risks Lurking in Possible Biotech Buyout24/7 Wall St.(Wed, Sep 18)
Key Statistics
| Forward P/E (1 yr): | 15.54 |
|---|
| P/S (ttm): | 4.73 |
|---|
| Ex-Dividend Date: | 04-Sep-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 6.85 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 1.65 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | 1.60 |
|---|
Business Summary
Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM).
View More